Abstract
We report a case of two siblings with progressive myoclonus epilepsy whose parents were not consanguineous. Their clinical symptoms were typical of Lafora disease (LD), but skin biopsies revealed no Lafora bodies. Whole-exome sequencing identified a recurrent homozygous frameshift variant in the NHLRC1 gene in both siblings. The genetic analysis was useful for the diagnosis of LD, as neither consanguinity nor Lafora bodies were found.
Lafora disease (LD, OMIM # 254780) is one of progressive myoclonus epilepsy (PME) with a mode of autosomal recessive inheritance. The symptoms usually start in the teenage years, and development is normal before the onset of seizures. The electroencephalogram (EEG) shows occipital spike-and-slow waves in the early stage of the disease. The occipital seizures with visual onset symptoms and myoclonus are easily induced by intermittent photic stimulation. Mental dysfunction and ataxic movement progress rapidly in a year1. EPM2A and NHLRC1 (EPM2B, RefSeq accession number NM_198586.2) are well-known causative genes for LD. More than 80% of LD patients carry variants in either gene; however, there is a possibility that another candidate gene may be involved in LD pathogenesis because some LD patients lack variants in either of them2,3. In the Japanese population, variants in NHLRC1 are the most frequent cause of LD4. Here, we report two Japanese siblings with LD carrying a homozygous variant in the NHLRC1 gene.
The proband (Fig. 1a; III-4) was born as the second child of unrelated Japanese parents. Her father was born in a town of northern Kyusyu and was healthy. Her mother was born in another town of northern Kyusyu and had a history of thyroid cancer. The patient had been a smart student until she suffered a generalized tonic clonic convulsion (GTC) at the age of 12 years. The initial symptom preceding GTC was visual hallucination. EEG showed occipital sporadic spikes and continuous slow waves in the bilateral occipital regions (Fig. 2a). She sometimes suffered visual hallucinations as a seizure manifestation and developed eyelid myoclonus. Six months after her first seizure, she experienced a second GTC and was diagnosed as having idiopathic occipital epilepsy with secondary generalization. She was prescribed carbamazepine but began to experience weekly GTCs and eyelid and generalized myoclonic seizures. Her cognitive and motor functions declined rapidly.
The proband was referred to our hospital at the age of 14 years. Myoclonic movement was occasionally observed in her fingers and eyelids. An examination of peripheral blood cells (PBCs) and sera showed insignificantly elevated hepatic enzyme levels. Urine and cerebrospinal fluid test results were normal. EEGs showed slow background activity, frequent generalized slow waves, and generalized and focal spikes (Fig. 2b). Bilateral diffuse slow waves intermingled with spikes were easily induced by intermittent photic stimulation (Fig. 2c). Fundoscopy revealed no abnormality. A somatosensory evoked potential (SEP) analysis showed a giant SEP. A brain magnetic resonance imaging scan showed moderate cerebral and cerebellar atrophy (Fig. 2d). These electro-clinical findings suggested LD, but Lafora bodies were not found by palm skin or rectal mucosal biopsy. We sent genomic DNA isolated from her PBCs to a company for analyses of the EPM2A and NHLRC1 genes. Upon analysis, the company reported no variants in either EPM2A or NHLRC1. Furthermore, we excluded the following diseases: Gaucher disease by a glucocerebrosidase enzyme assay in fibroblasts and the absence of Gaucher cells in the bone marrow; Unverricht–Lundborg disease and Dentato-rubro-pallido-luysian atrophy by genetic examinations; and mitochondrial disease by the lactate and pyruvate levels in the serum and cerebrospinal fluid.
At the age of 16 years, the proband became bedridden. She continuously had focal and generalized myoclonus and seizures despite combination therapy with sodium valproate, clonazepam, lamotrigine, and topiramate. Brain MRI showed progression of cerebellar atrophy when she was 17 years old (Fig. 2e).
The younger sister of the proband (Fig. 1a; III-5) experienced a similar GTC following visual hallucinations and myoclonus since the age of 11 years. She was also of normal intelligence before disease onset, and memory disturbance and ataxia appeared a few years after onset. The subsequent onset in this younger sister strongly suggested that the two sisters suffered from an inherited PME.
When the proband was 17 years old and her younger sister was 15 years old, we performed whole-exome sequencing. The results showed that both patients had a homozygous frameshift variant in the NHLRC1 gene (Fig. 1b), NM_198586.2 (NHLRC1):c.898del p. [Ser300Valfs*13], resulting in the substitution of the Serine300 residue with Valine followed by a premature stop codon at position 312. Sanger sequencing confirmed that their parents had a heterozygous NM_198586.2(NHLRC1):c.898del: p. [Ser300Valfs*13] variant. We requested re-examination of NHLRC1 from the company that performed the original genetic analysis, and the variant was confirmed. The variant was not found in the Exome Variant Server database (http://evs.gs.washington.edu/EVS/), the Genome Aggregation Database (gnomAD) (http://gnomad.broadinstitute.org), or in our in-house 575 control exomes. The same variant had been reported by Singh et al.4; therefore, it was classified as pathogenic in accordance with the American College of Medical Genetics and Genomics variant classification guidelines5.
Considering the clinical symptoms and the results of genetic examinations, we diagnosed both patients with LD due to a homozygous frameshift variant in the NHLRC1 gene.
The siblings exhibited the typical clinical characteristics of LD. Their PME with occipital seizures and photosensitivity appeared during their teenage years. Their intellectual and motor functions declined rapidly from the onset. Lafora bodies, a characteristic feature of LD showing deposition of abnormal glycogen in the cytoplasm, were not found in our cases, and definitive diagnosis was performed by detection of the NHLRC1 variant. The prevalence of EPM2A or NHLRC1 variants in classical LD patients was much higher (93%) than the detection rate of Lafora bodies (67%)6. Therefore, mutation screening of the EPM2A and NHLRC1 genes is an effective and recommended method for the diagnosis of LD.
High allelic heterogeneity has been observed for LD3. It suggests that the variants occur from single events in most cases. On the other hand, several recurrent variants in the NHLRC1 gene, such as the missense variant c.76T>A: p.Cys26Ser (rs28940575, Allele Frequency (AF) in gnomAD = 4.529 × 10−6) in French-Canadians, the frameshift variant c.468_469delAG: p.Gly158Argfs*17 (rs781300542, AF = 1.226 × 10−5) in Omani, the frameshift variant c.1049_1050del: p.Glu350Glyfs*41 (not registered in gnomAD) in the Serbian/Montenegrin and the missense variant c.205C>G:p.Pro69Ala (rs28940576, AF = 9.33 × 10−5) in Mediterranean countries, were reported3,7,8. These variants are very rare, but each variant was frequently found in LD families living in a specific region, suggesting a founder effect.
Previous studies described that NHLRC1 is the common causative gene in Japanese LD patients, and five missense variants and a single base-pair deletion leading to a frameshift variant have been identified4. None of these variants are shared with the other five families in previous reports. The NM_198586.2(NHLRC1):c.898del:p.[Ser300Valfs*13] variant found in our patients has not yet been registered in public databases; however, the same homozygous variant was found in another Japanese LD patient born to non-consanguineous parents4. Our data suggest that the NM_198586.2 (NHLRC1):c.898del:p.[Ser300Valfs*13] variant may originate from the same ancestor in the limited northern Kyusyu districts, but further analyses are needed to confirm the founder effect of the c.898del variant in the limited districts.
In conclusion, we found a homozygous NHLRC1 variant in Japanese LD siblings without consanguineous marriage. The genetic analysis was a minimally invasive and highly sensitive diagnostic method. Therefore, it should be recommended as the first step for LD diagnosis instead of the histological examination.
HGV Database
The relevant data from this Data Report are hosted at the Human Genome Variation Database at 10.6084/m9.figshare.hgv.2327.
Conflict of interest
The authors declare that they have no conflict of interest.
Footnotes
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.de Siqueira LF. Progressive myoclonic epilepsies: review of clinical, molecular and therapeutic aspects. J. Neurol. 2010;257:1612–1619. doi: 10.1007/s00415-010-5641-1. [DOI] [PubMed] [Google Scholar]
- 2.Chan EM, et al. Progressive myoclonus epilepsy with polyglucosans (Lafora disease): evidence for a third locus. Neurology. 2004;63:565–567. doi: 10.1212/01.WNL.0000133215.65836.03. [DOI] [PubMed] [Google Scholar]
- 3.Singh S, Ganesh S. Lafora progressive myoclonus epilepsy: a meta-analysis of reported mutations in the first decade following the discovery of the EPM2A and NHLRC1 genes. Hum. Mutat. 2008;30:715–723. doi: 10.1002/humu.20954. [DOI] [PubMed] [Google Scholar]
- 4.Singh S, et al. Mutations in the NHLRC1 gene are the common cause for Lafora disease in the Japanese population. J. Hum. Genet. 2005;50:347–352. doi: 10.1007/s10038-005-0263-7. [DOI] [PubMed] [Google Scholar]
- 5.Richards S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 2015;17:405–424. doi: 10.1038/gim.2015.30. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Lesca G, et al. Novel mutations in EPM2A and NHLRC1 widen the spectrum of Lafora disease. Epilepsia. 2010;51:1691–1698. doi: 10.1111/j.1528-1167.2010.02692.x. [DOI] [PubMed] [Google Scholar]
- 7.Kecmanović M, et al. Clinical and genetic data on Lafora disease patients of Serbian/Montenegrin origin. Clin. Genet. 2016;89:104–108. doi: 10.1111/cge.12570. [DOI] [PubMed] [Google Scholar]
- 8.Gómez-Abad C, et al. Lafora disease due to EPM2B mutations: a clinical and genetic study. Neurology. 2005;64:982–986. doi: 10.1212/01.WNL.0000154519.10805.F7. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
The relevant data from this Data Report are hosted at the Human Genome Variation Database at 10.6084/m9.figshare.hgv.2327.